Scientists have discovereded the two key processes that allow cancer cells to change the way they move in order to spread through the body, according to a new study.
Researchers used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model. Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity. The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors.
Outils 
